Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-09-18
2008-05-13
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C530S350000
Reexamination Certificate
active
07371386
ABSTRACT:
The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.
REFERENCES:
patent: 4341761 (1982-07-01), Ganfield et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427783 (1984-01-01), Newman et al.
patent: 4444887 (1984-04-01), Hoffmann
patent: 4466917 (1984-08-01), Nussenzweig et al.
patent: 4472500 (1984-09-01), Milstein et al.
patent: 4491632 (1985-01-01), Wands et al.
patent: 4493890 (1985-01-01), Morris
patent: 4517304 (1985-05-01), Stott et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5942234 (1999-08-01), Ralsten et al.
patent: 6146633 (2000-11-01), Stevens
patent: 6797809 (2004-09-01), Chien et al.
patent: 7135185 (2006-11-01), Weiner et al.
patent: 2004/0096822 (2004-05-01), Chien et al.
patent: 0 116 201 (1984-08-01), None
patent: 0 120 551 (1984-10-01), None
patent: 0 164 556 (1985-12-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 360 088 (1990-03-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 468 527 (1992-01-01), None
patent: 0 725 824 (1996-08-01), None
patent: 0 759 937 (1997-03-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 90/11089 (1990-10-01), None
patent: WO 90/14436 (1990-11-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/04205 (1993-03-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 93/16126 (1993-08-01), None
patent: WO 93/18054 (1993-09-01), None
Barrett, J.T., Basic immunology and its medical application, Second Edition, pp. 4-17 (1980).
Berzofsky et al., Chapter 8, from : “Fundamental Immunology, Second Ed.” Ed. W.E. Paul, Raven Press Ltd., pp. 176, 177, 201, 202. (1989).
Botarelli, P., et al., “T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection”,Gastroenterology104:580-587. (1993).
Brennan, M., et al., “The follicle cells are a major site of vitellogenin inDrosophila melanogaster”, Dev. Biol.89:225-236. (1982).
Broach, R., “Construction of High Copy Yeast Vectors Using 2-.mu.m Circle Sequences,”Meth. Enz.101:307-325. (1983).
Cha, et al., “At least five related, but distinct, hepatitis C viral genotypes exist,”PNAS USA89:7144-7148 (1992).
Chakrabarti, et al., “Vaccinia Virus Expression Vector: Coexpression of .beta.-Galactosidase Provides Visual Screening of Recombinant Virus Plaques,”Mol. Cell Biol.5(12):3403-3409 (1985).
Chan, et al., “Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants”J Gen Virol73:1131 (1992).
Choo et al., “Vaccination of chimpanzees against infection by the hepatitis C virus”,Proc. Natl. Acad. Sci. USA91:1294-1298. (1994).
Choo, Q.L., et al., “Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis”,Br. Med. Bull.46(2):423-441 (1990).
Choo, Q.L., et al., “Genetic organization and diversity of the hepatitis C virus”,Proc. Natl. Acad. Sci.USA 88:2451-2455. (1991).
Choo, Q.L., et al., “Hepatitis C virus is a distant relative of the flaviviruses and pestiviruses”, in Proceedings of the International Meeting on Non-A, Non-B Hepatitis, Shikata, T. et al. (eds.), Tokyo, Japan, Amsterdam: Elsevier, pp. 47-52. (1991).
Choo, Q.L., et al., “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome”,Science244:359-362. (1989).
Choo, Q.L., et al., “Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach”,Seminars in Liver Disease12(3):279-288. (1992).
Coffin, et al., (eds.), RNA Tumor Viruses, 2nd Edition, Cold Spring Harbor Laboratory, New York, 1985, 2:17-73 (1985).
Cuypers, H.T., et al., “Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus”,J. Clin. Microbiol,30(12):3220-3224. (1992).
Cuypers, H.T.M., et al., “Analysis of genomic variability of hepatitis-C virus”,J. Hepatology13(4):S15-S19. (1991).
DeBoer, et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,”Proc. Natl. Acad. Sci. USA80(1):21-25. (1983).
Erickson, A.L., et al., “Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C”,J. Immunol.151(8):4189-4199.(1993).
Esquivel, et al., “T Cell Recognition of Hepatitis C Virus in Patients with Chronic Hepatitis C,”Gastroenterology,vol. 104, No. 4, Part 2, Apr. 1993, one page.
Esumi, et al., “In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralilze heterologous hepatitis C virus,”Vaccine20:3095-3103. (2002).
Fahey, et al., “Status of immune-based therapies in HIV infection and AIDS,”Clin. Exp. Immunol.,88:1-5. (1992).
Farci, et al., “Prevention of Hepatitis C Virus Infection in Chimpanzees by Hyperimmune Serum Against the Hypervariable Region 1 of the Envelope 2 Protein,”PNAS93(26):15394-9 (1996).
Fausto-Sterling, A., et al., “Analysis of a newly-isolated temperature-sensitive maternal effect mutation ofDrosophila melanogaster”, J. Exper. Zoo.200:199-209 (1976).
Fiers, et al., “Complete nucleotide sequence of SV40 DNA,”Nature273:113-120 (1978).
Goeddel, et al., “Synthesis of human fibroblast interferon byE. coli,” Nucl. Acids Res.8(18):4057-4075 (1980).
Guntaka, R.V., et al., “Effect of 5-Methyllcytidine on virus production in avian sarcoma virus-infected chicken embryo cells”,Virology29(2):475-482 (1979).
Guntaka, R.V., et al., “Effect of dibutyrlcyclic AMP on intracellular levels of avian sarcoma virus specific RNA”,Nature274:274-276 (1978).
Hattori, et al., “Cross-Reactivity of Anti-Hypervariable Region Antibody of HCV Infected Patients,” 4thInternat'l Meeting on Hepatitis C Virus and Related Viruses, Mar. 6-10, Kyoto, Japan, p. 119 and abstract p. 306 (1997).
Hess, et al., “Cooperation of glycolytic enzymes,”J. Adv. Enzyme Reg.7:149-167 (1968).
Hijikata, et al., “Hypervariable regions in the putative glycoprotein of hepatitis C virus,”Biochemical and Biophysical Research Communications175(1):220-228 (1991).
Hitzeman, et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,”J. Biol. Chem.255(24):12073-12080 (1980).
Holland, et al., “The primary structures of two yeast enolase genes,”J. Biol. Chem.256(3):1385-1395 (1981).
Holland, et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,”Biochem.17(23):4900-4907 (1978).
Houghton, M., et al., “The hepatitis C virus: Genetic organization, persistence, and vaccine strategies,” in Viral Hepatitis and Liver Disease, Nishioka, K. et al. (eds.), Springer
Houghton Michael
Weiner Amy J.
Campell Bruce R.
Horning Michelle
Novartis Vaccines and Diagnostics Inc.
Robins & Pasternak LLP
LandOfFree
Conserved motif of hepatitis C virus E2/NS1 region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conserved motif of hepatitis C virus E2/NS1 region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conserved motif of hepatitis C virus E2/NS1 region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987663